University at Buffalo - The State University of New York
Skip to Content
The Potential of p38 MAPK Inhibitors to Modulate Periodontal Infe...: Ingenta Connect

Subscribed Content The Potential of p38 MAPK Inhibitors to Modulate Periodontal Infections

Download Article:

Subscribed Content You have access to the full text electronic article

You, or the institution you are accessing from, have subscription access to this publication.

 Download
(PDF 2236.7880859375 kb)
 
Periodontal disease initiation and progression occurs as a consequence of the host immune inflammatory response to oral pathogens. The innate and acquired immune systems are critical for the proper immune response. LPS, an outer membrane constituent of periodontal pathogenic bacteria, stimulates the production of inflammatory cytokines IL-1β, TNFα, IL-6 and RANKL either directly or indirectly. In LPS-stimulated cells, the induction of cytokine expression requires activation of several signaling pathways including the p38 MAPK pathway. This review will discuss the significance of the p38 MAPK pathway in periodontal disease progression and the potential therapeutic consequences of pharmacological antagonism of this pathway in the treatment of periodontal diseases.





No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: Periodontal diseases; bone loss; cytokine; experimental periodontitis; inflammation; innate immunity; p38 MAPK; p38 inhibitors

Document Type: Research Article

Publication date: 2009-01-01

More about this publication?
  • Current Drug Metabolism aims to cover all the latest and outstanding developments in drug metabolism and disposition. The journal serves as an international forum for the publication of timely reviews in drug metabolism. Current Drug Metabolism is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments. The journal covers the following areas:

    In vitro systems including CYP-450; enzyme induction and inhibition; drug-drug interactions and enzyme kinetics; pharmacokinetics, toxicokinetics, species scaling and extrapolations; P-glycoprotein and transport carriers; target organ toxicity and interindividual variability; drug metabolism and disposition studies; extrahepatic metabolism; phase I and phase II metabolism; recent developments for the identification of drug metabolites and adducts.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more